Fierce Pharma September 27, 2024
AstraZeneca and Daiichi Sankyo’s Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences’ Kite will bow out of its China joint venture with Fosun Pharma. Korea’s Yuhan ended an EGFR inhibitor partnership with Johnson & Johnson but signed an HIV drug supply deal with Gilead. And more.
1. AstraZeneca, Daiichi’s Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) failed to improve overall survival compared with chemotherapy in patients with previously treated HR-positive, HER2-low or -negative breast cancer in the phase 3 TROPION-Breast01 trial. The study previously met its other dual primary endpoint, progression-free survival, and the FDA is reviewing an application for the TROP2 antibody-drug conjugate based...
Today's Sponsors
Today's Sponsor